Results 151 to 160 of about 221,174 (192)
Some of the next articles are maybe not open access.
Bioanalysis of Meningococcal Vaccines
Bioanalysis, 2010Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Neil, Ravenscroft +2 more
openaire +2 more sources
Meningococcal conjugate vaccines
Expert Opinion on Pharmacotherapy, 2004Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
Shanta M, Zimmer, David S, Stephens
openaire +2 more sources
Current Pharmaceutical Design, 2007
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
Neisseria meningitidis is a major world-wide cause of meningitis. N. meningitidis related diseases have become more pronounced in the last decade and changes in meningococcal-associated disease have opened new opportunities for prevention and vaccine development. Although multivalent vaccines have been developed against the N. meningitidis serogroups A,
openaire +2 more sources
The Future of Meningococcal Vaccines
Pediatric Infectious Disease Journal, 2005Despite antibiotics and supportive care ~10% of persons with meningococcal infection die 9-19% have sequelae (skin grafting amputation hearing deficits) and outbreaks often provoke panic. Meningococcal meningitis is the main cause of bacterial meningitis in children in the United States.
C Mary, Healy, Carol J, Baker
openaire +2 more sources
Meningococcal conjugate vaccines
Expert Opinion on Biological Therapy, 2005Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire +2 more sources
Meningococcal Vaccines and Vaccine Developments
2003Despite rapid advances in the diagnosis of bacterial infections and the availability of effective antibiotics, meningococcal disease continues to represent a substantial public health problem for most countries (1-4). Disease usually develops rapidly, is notoriously difficult to distinguish from other febrile illnesses, and generally has a high case ...
openaire +2 more sources
2003
The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
P, Farrington, E, Miller
openaire +2 more sources
The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
P, Farrington, E, Miller
openaire +2 more sources
Meningococcal vaccine in travelers
Current Opinion in Infectious Diseases, 2007New vaccines to prevent meningococcal disease have been licensed in recent years. It is therefore timely to discuss current vaccine strategies pertinent to international travelers in relation to the changing epidemiology.Serogroup W135 achieved epidemic status in Africa in 2002, and then largely disappeared over a short time period. The year 2006 saw a
openaire +2 more sources
Meningococcal Disease and Vaccines
Pediatric Annals, 2001P, Dull, N, Rosenstein
openaire +2 more sources